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Abstract
Background: Smoking rather than injecting heroin has become more common over the last 20 
years. Although there is an increasing body of evidence describing high levels of chronic obstructive 
pulmonary disease (COPD) in people who smoke heroin, there is limited evidence documenting the 
impact of the long- term condition on this population group.
Aim: This study aimed to describe the experiences of people who smoke heroin with COPD in 
Liverpool, UK.
Design & setting: Participants were purposefully sampled for this qualitative study. They included 
adults enrolled in an opioid replacement clinic run by Addaction in Liverpool, who had already 
engaged with spirometry testing for COPD as part of a previous study.
Method: Semi- structured interviews were performed with participants with spirometrically confirmed 
COPD in opioid replacement clinics. Data were analysed using a framework analysis approach.
Results: Sixteen potential participants were invited to take part in the study, of which 10 agreed and 
were interviewed. Three themes common to all interviews were identified: functional measures of lung 
health that impacted on their activities of daily living; inhaler and medication perceptions with erratic 
use that was not concordant with their prescription; and the impact of difficulties accessing care.
Conclusion: These findings, along with previous studies highlighting the prevalence of COPD in 
this population, warrant efforts to integrate community COPD and opioid replacement services to 
improve outcomes for this vulnerable population.
How this fits in
There is a growing body of evidence of high levels of COPD in people who smoke heroin. This 
appears to happen at an earlier age than the general population. This qualitative study investigates 
the experiences of these patients and provides clinicians with new insights into the challenges facing 
this population. These results can be used to help guide the planning of future primary care services 
for this group of patients.
Introduction
Over the last two decades, people who use heroin have increasingly smoked rather than injected the 
drug, understanding this to be a method of harm reduction.1,2 This has, however, led many people 
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who smoke heroin to develop COPD at an earlier age than typically seen in those who exclusively 
smoke tobacco.3,4 A recent study in Liverpool demonstrated that approximately 50% of people who 
smoke heroin have COPD or its overlap syndrome with asthma.3 Those with COPD reported extensive 
respiratory symptoms, such as shortness of breath, cough, and wheeze,5–7 which are likely to lead to 
increased hospital admissions.8–10 Screening people who use heroin for COPD may be an important 
part of providing care early in the course of the disease and limiting the burden of acute hospital 
care.4,11
There is limited evidence regarding patient experience among people who use heroin. The study, 
therefore, sought insight into the experience and challenges faced by people who smoke heroin with 
COPD in order to shape future screening and treatment services. This qualitative study examined 
the lived experience of those with symptoms and a diagnosis of chronic lung disease, and of their 
experience of interfacing with healthcare services to access treatment.
Method
Semi- structured interviews were conducted with people who smoke heroin diagnosed with COPD as 
part of a screening programme between December 2017 and April 2018.
Study context
The interviews were carried out in Addaction community opioid replacement clinics in Liverpool 
as part of a COPD screening programme. Addaction is a large independent charity commissioned 
by the local city council public health department. The screening programme has been previously 
reported.3,12 Between December 2015 and June 2016, participants had been evaluated using 
respiratory symptom- specific questionnaires, and spirometry to test their lung function. Follow- up 
screening took place between December 2017 and April 2018.3,12
Recruitment
Within Addaction clinics for opioid replacement therapy, key workers were asked to identify potential 
participants for the qualitative study. All had been diagnosed with COPD during baseline screening 
and were current or previous smokers of heroin. Potential participants were given study information 
prior to their appointment and if they agreed to being interviewed, a key worker who knew them 
notified the study team. The key worker was not present during the interviews, but was available for 
support as necessary. Written informed consent was obtained from all participants.
Data collection
Interviews were led by a researcher (PG) independent of the quantitative screening study, with 
experience of qualitative research and extensive medical knowledge of COPD. The researcher was 
aware the participant had COPD but knew no further clinical details. The interviews took place 
within the two large Addaction clinic sites in Liverpool, in rooms separate from the clinics to remove 
the participants from the clinical environment, and with refreshments provided. The researcher 
followed the topic guide, which included: reported symptoms or problems; understanding of COPD; 
understanding of medications; and experience of access to care. Open questions were asked, with 
pre- prepared probing questions to gain further information (see Supplementary Appendix S1). All 
interviews were digitally recorded and identified by participant number only.
Analysis
A framework analysis approach was used, taking five steps to results: familiarisation; coding; 
developing and applying a framework; charting; and interpretation.13 Each interview was transcribed 
verbatim, and the transcripts were read through by two researchers (RN and PG) for familiarisation. 
Following this, RN and PG agreed on the major coded themes based on the topic guide. The data were 
coded separately in Microsoft Excel, with the transcripts colour- coded for each theme in Microsoft 
Word. These codes were then shared with the wider research team (RN, PG, JR, HB) and a thematic 
framework was developed through discussion until a consensus was reached on the mapping of the 
codes. The themes were shared with Addaction staff members who were part of the research team to 
ensure they were accurate to the setting and true to the original topic guides (TB and KM).
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Results
Sixteen potential participants were invited, 10 of whom agreed to take part and were interviewed. 
The age range of those interviewed was 47–59 years, with eight males and two females taking part; 
all were white. The participants had a range of COPD severity measured by the Global Initiative for 
Obstructive Lung Disease classifications (mild n = 4, moderate n = 3, severe n = 3).14 All were taking 
opioid replacement therapy, with seven reporting they still smoke heroin. Following the interview 
framework, three themes common to all interviews were identified: functional measures of lung health 
that impacted on their activities of daily living; inhaler and medication perceptions with erratic use 
that was not concordant with their prescription; and the impact of difficulties accessing care.
Functional measures of lung health
All participants described their COPD in relation to the degree of functional limitation imposed by 
their symptoms. None of the participants described their COPD or lung disease in terms of medical 
outcomes such as spirometry results or breathlessness scores. Every participant had concerns about 
how COPD was affecting their everyday activities of daily life:
'You know every day I get up in the morning, I go to make a cup of coffee and I come back 
in and sit down and I’m gasping for breath and I can’t catch my breath, I just can’t get it, you 
know what I mean?' (Interview 5)
'I mean I often don’t go out, I struggle carrying shopping, I use one of them now, a bag over 
your shoulder, with the string, they help me to walk, a lot better. One time, I was putting the 
bags down, walk a bit, get my breath, again and again, oh God, it was horrendous.' (Interview 
10)
Participants described how their functional capacity had deteriorated over time. Eight participants 
recognised a worsening over a period of months or years. COPD was not explicitly mentioned in these 
cases, rather the participants described problems with their 'lungs' or 'chest' but did not necessarily 
attribute their problems to, or label their condition as, COPD:
'I was just speedy me. I was just one of them people, but now, now I just can’t even, even 
when my son was 7, I mean he’s 15 now, I was still doing the garden but I couldn’t breathe. 
I’ve stopped trying to do the garden I mean coz that nearly killed me, I mean it, bad 
palpitations, I think it would have killed me that day, my neighbour came out and said "go in, 
get in now!" and stayed with me and everything.' (Interview 9)
'I can’t any more, I was quite active say 10 years ago, but now I can’t run, can go slow on 
a bike but that’s it, couldn’t run if I wanted to ... yeah, just from walking, or as I’ve said just 
getting out of bed, I can walk to the landing to look out the window and be standing panting, 
thinking "where’s the inhalers" and it’s only when I have the inhalers that it seems to calm me 
down a bit.' (Interview 3)
Two participants did not perceive their chest to be a significant problem; both described functional 
limitation, but reported it as normal for them:
'I did run for the bus the other day and feel a bit out of breath, but most people would 
wouldn’t they? Running for the bus and exerting themselves, you know, at 8 o’clock in 
the morning … I’ve got to be very fit and active every single day … So my chest isn’t too 
bad considering what I’ve put into it over the years, at least from my perspective it’s not.' 
(Interview 2)
'No … no it doesn’t stop me, and the inhalers I don’t use them every day, only when I need 
to, only when I’m coughing and short of breath I’ll use them then … yeah but only when I’m 
coughing, sometimes I cough and I’m nearly puking ... maybe two or three times a week.' 
(Interview 4)
Inhalers and medication perceptions
All participants reported taking at least one inhaler and talked about them consistently during the 
interviews. Of the 10 participants interviewed, seven reported that they had recently borrowed other 
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people’s inhalers or medication to help their chest. The reasons for this were not always identifiable, 
but access to medication was a frequent difficulty:
'... well the last one I needed I got off me cousin coz she had a spare.' (Interview 4)
'My girlfriend has one of those nebuliser things so I just throw myself on that, and erm, that 
kind of makes me feel ok.' (Interview 6)
'If there’s antibiotics in the house then I’ll use them instead [of going to a doctor] … it’s like, 
I’ve been around drugs most of my life, so I’m not afraid to try an antibiotic or something if I 
think it might help me … well the wife has got asthma there, so err she got inhalers, a brown 
one and a blue one, and I’ll use them every now and again … They’ve told me COPD is 
different to asthma so instead of using the wife’s stuff, I might need something else, a different 
one for my condition might be better.' (Interview 7)
Participants also reported the use of metered- dose inhalers (MDIs) as drug pipes, either by 
themselves or others:
'We used to make bongs out them, the blue one [salbutamol MDI], years ago, but God I 
couldn’t even look at doing that now it knocks me sick.' (Interview 9)
'You just [describes process of converting inhaler into a drug pipe] ... Yeah yeah the blue ones, 
the hollow tube […] I’ve seen a lot of people use them like that, like "rock pipes" we called 
them ... So it’s a common thing to do ... It sounds mad that people are using things meant to 
help you breathe for that stuff doesn’t it?' (Interview 4)
There was generally poor knowledge and understanding surrounding inhalers, with participants 
confused between the name of the inhaler and the colour; for example, describing a 'blue inhaler' but 
pointing to a purple (Seretide) inhaler (interview 1). In general, participants described high usage of 
the 'blue inhaler' (salbutamol) and inconsistent use of long- acting medication such as tiotropium or 
formoterol. Participants reported that they used inhalers as and when they needed them, and there 
appeared to be a lack of understanding of using longer- term inhalers as prevention for some of the 
functional problems they described:
'I use the inhalers carefully, don’t waste them you know, use them as and when I feel I really 
need them, I don’t use them for the fun of it, I’ll only use them when I feel as though I’m 
struggling.' (Interview 8)
'Talking about the “blue and pink”? Nah I don’t use any of them regularly, only when I get 
bouts of it.' (Interview 4)
Impact of access to care
The difficulty in accessing both primary care appointments and hospital appointments was a recurring 
theme. The participants described travel to and from appointments as a barrier to attending both the 
GP surgery and the hospital. In some circumstances the cost of travel was prohibitive and in others it 
was the practicalities of getting out of the house while being unwell. The participants suggested that 
they may attend more often if access to care was easier:
'... well it’s two buses away, and it kills me to get there, but I love that doctor so I make the 
effort if I need to.' (Interview 1)
'It can be a bit of a task though, with the breathing and that, sometimes I only have to walk 
around the corner and I’m having a bad time ... yeah well I have to walk here as well so that 
can be hard in itself, stop and rest about 20 times ... you’d see me sat down on the road and 
all that, you know what I mean?' (Interview 6)
'I just can’t get there, even if I phone a taxi to come and take me, I just can’t get up and down 
the stairs.' (Interview 8)
The experience that participants had of their GPs and hospital doctors varied throughout the 
interviews, with participants describing their GP as 'marvellous' (interview 1) and saying 'I can’t fault 
him' (interview 10). All participants reported that seeing their own GP was difficult; either they saw a 
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locum, which they reported as a negative experience, or that getting an appointment via reception 
was difficult:
'... well it’s hard to get an appointment at the doctors, to get my script, and God did I feel it 
when I ran out, really bad.' (Interview 1)
'... you know the credit on your phone to ring up, and you know when they say to ring at 8 
o’clock in the morning, well try using somebody else’s phone, like I’ve had to use before, at 
eight in the morning. That’s no good to me.' (Interview 10)
'... maybe receptionists, when you phone up you’ve got to phone at certain times, waiting 
to get through to the receptionists, you see it’s like you wait for the phones to turn over at 
8:20am and you might not get through ‘til 9:20am and they’ve all gone, so, that’s not good ... 
like I could have a problem like today, and I’ll go in or ring up and they’ll say "yeah we can fit 
you in in 2 weeks’ time", well hang on, you know?’ (Interview 8)
The participants generally reported that they did not attend hospital appointments. There were a 
variety of reasons for this, including the feeling of stigma or that chest problems were ‘self- inflicted’. 
Several participants avoided secondary care environments owing to negative associations with, for 
example, a dying relative, or a negative experience with the hospital staff:
'I think they’re rushed off their feet, so you know, I think there’s sicker people than me to be 
seen to … coz mine are self- inflicted, like they see sick children and it just shows you that I’ve 
done this to myself, you know? ... because it’s self- inflicted isn’t it? I just feel embarrassed 
wasting the national health money ... ' (Interview 1)
'... well they can’t do nothing can they, the doctors can’t do nothing for my chest the way it is, 
I have inhalers, I asked them about nebulisers, they said I don’t need a nebuliser, so, but I think 
I do like ... I don’t know, I feel like they just look at you and think "ah its self- inflicted" and that 
... ' (Interview 5)
' [when admitted with chest problem] I’m on certain medication that they just won’t give you, 
like the methadone, they just won’t give you that, so I’ve got to lie there, like if I go in on a 
Friday I’ve got to lie there until Monday, with no nothin’. So you’re in bits by Monday, they 
sort your dose out, I know people might try and cheat the system, but you know, it goes 
on, I’m not going to abuse it and as doctors and nurses you’ve got to think "is this man on 
this?". For one time in the hospital I was on 360 ml a day, so when the doctors read that they 
thought "F*ck off no way", you’d say as well. I mean I’m not on that now. They say to you 
get a stat dose of 20 ml, but what that’s gonna do for me when I’m on 360? It doesn’t help. 
It’s experiences like that, the last thing I’d want to do is ring an ambulance if I can help it.' 
(Interview 8)
Discussion
Summary
Using qualitative interviews, this study has shown the key challenges for this cohort are lung health 
symptoms that impacted on their activities of daily living; inhaler and medication perceptions, with 
erratic use that was not concordant with their prescription; and the impacts of difficulties accessing 
care. These themes occurred throughout the interviews and could help inform and develop respiratory 
services for this group of patients.
Strengths and limitations
The main limitation of this study is the small number of interviews conducted and the breadth of the 
interviews conducted. It may have added to the depth of knowledge if healthcare providers had also 
been interviewed, and further study in this area would be informative. The participants who declined 
to take part may have led to bias, with those happier to engage or those with strong opinions about 
their COPD potentially more likely to take part. This study has, however, offered a new and unique 
view on the possible barriers facing people with COPD who smoke heroin.
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Comparison with existing literature
The participants’ main focus was the functional limitation that they experienced in their activities of 
daily living as a result of their COPD. No participant discussed the details of their medical diagnosis, 
the staging of their COPD or used medical scoring, such as MRC (Medical Research Council) and 
COPD assessment test (CAT), to describe their COPD. To the best of the authors' knowledge, there 
are no studies that specifically describe the impact and functional limitations of COPD in people 
who smoke heroin; however, the themes identified in this study are similar to studies of people who 
smoke tobacco. In a large pan- European study examining patients with COPD and their experience 
of acute exacerbations, there was wide variability in reported symptoms between patients (reported 
at 62.7%), high levels of self- medication, and poor understanding of their condition.14 The impact 
of COPD- related symptoms on activities of daily living has been evaluated previously, with there 
being a high prevalence of impaired functioning among patients with COPD across a wide range of 
domains. The impairment does not clearly correlate with standard clinical measures such as degree of 
airflow obstruction or level of dyspnoea.15,16 Furthermore, functional limitation was common among 
the participants in the study and was often deemed to be ‘normal’ by individuals. Relying on objective 
measures of COPD severity in this patient population may not identify individuals who would benefit 
from more targeted interventions, such as pulmonary rehabilitation, aiming to improve symptoms and 
level of functioning with regards to activities of daily living.
In general, the study participants appeared to be taking COPD medication in an irregular and 
often self- directed manner. In some, inhalers were used as a vehicle for smoking drugs rather than 
for their intended purpose. The engagement with the primary care system in the UK was mixed, with 
some participants having an excellent experience of their GP, while others found significant barriers 
to attending primary care, with travel and access to the GP being the principle negative factors. 
Participants universally found accessing hospital treatment difficult, with stigma and a feeling of 
having a 'self- inflicted' illness limiting attendance at the hospital.
Poor adherence and a lack of knowledge or trust in medication has been reported in other studies 
of COPD patients, with overuse, underuse, and alteration from medication schedule commonplace.17 
In a cross- sectional study of 173 patients with COPD attending outpatient clinics, 29.5% of attendees 
had 'low adherence' to medication.18 The theme of accessing prescription medication from peers or 
family members is also not unique to the study population, with another study on students finding 
that those who access medication from peers were also more likely to use illicit drugs.19 Stigma and 
significant barriers to accessing both primary and secondary care are common across illicit drug users, 
with reports of 'dissonant care' commonplace with other qualitative and narrative studies in this 
population, describing similar findings to the analysis of the interviews in the present study.20–23
Implications for research and practice
The data highlight important considerations in the development of COPD services for drugs users. 
Clinicians should consider functional outcomes as well as clinical outcomes and objective scoring 
systems when discussing COPD treatment with patients. There is potential that functional goals would 
be welcomed by this patient group and may help motivate the attendance to care and adherence to 
treatment. The use of self- medicated inhalers, nebulisers, and other drugs makes clinical assessment 
even more challenging in this population. It is highly likely that the standard methods of assessing 
'medication pick- up' at pharmacies does not provide an accurate picture, and that self- reported 
usage may be key to determining the real clinical need. Alongside this, the overuse of some inhalers, 
potentially as drug paraphernalia, adds to an already complex clinical picture. The access to respiratory 
care for this patient group is limited, with barriers including transport to hospitals and a feeling of 
stigma. There is potential that providing respiratory care centred around venues where patients 
attend opioid replacement therapy would improve continuity of care and assist in obtaining accurate 
medication histories. This research highlights the complex needs of people who smoke heroin with 
COPD and the need to consider their functional limitations, medication management, and access to 
care in future planning of respiratory services.
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